ZYMEWORKS INC. - COMMON STOCK

Zymeworks Announces Participation in Upcoming Investor Conferences

19 Aug 2025 03:00:00 By Nasdaq GlobeNewswire

Zymeworks Strengthens Board of Directors with Appointments of Greg Ciongoli and Robert E. Landry

11 Aug 2025 03:00:00 By Nasdaq GlobeNewswire

Zymeworks Provides Corporate Update and Reports Second Quarter 2025 Financial Results

07 Aug 2025 13:05:03 By Nasdaq GlobeNewswire

Zymeworks Announces FDA Clearance of Investigational New Drug Application for ZW251, a Novel Glypican 3-Targeted Topoisomerase 1 Inhibitor Antibody-Drug Conjugate

28 Jul 2025 03:00:00 By Nasdaq GlobeNewswire

Zymeworks to Report Second Quarter 2025 Financial Results and Host Conference Call on August 7, 2025

17 Jul 2025 03:00:00 By Nasdaq GlobeNewswire

Zymeworks Announces NMPA Approval of Zanidatamab in China for Adults with Previously Treated, Unresectable or Metastatic HER2-high expression (IHC3+) Biliary Tract Cancer

30 May 2025 03:00:00 By Nasdaq GlobeNewswire

Zymeworks Announces Presentations Highlighting Breadth of Oncology Portfolio at Upcoming Medical Conferences

22 May 2025 14:00:00 By Nasdaq GlobeNewswire

Zymeworks Announces Participation in Upcoming Investor Conferences

21 May 2025 03:00:00 By Nasdaq GlobeNewswire

Zymeworks Presents Preclinical Data on ZW1528 at the American Thoracic Society International Conference

19 May 2025 13:15:00 By Nasdaq GlobeNewswire

Zymeworks Provides Corporate Update and Reports First Quarter 2025 Financial Results

08 May 2025 13:04:03 By Nasdaq GlobeNewswire

Zymeworks Presents New Data from Multiple Development Programs at 2025 AACR Annual Meeting

25 Apr 2025 10:00:00 By Nasdaq GlobeNewswire

Zymeworks Appoints Dr. Sabeen Mekan as Senior Vice President, Clinical Development

21 Apr 2025 03:00:00 By Nasdaq GlobeNewswire

Zymeworks to Report First Quarter 2025 Financial Results and Host Conference Call on May 8, 2025

17 Apr 2025 03:00:00 By Nasdaq GlobeNewswire

Zymeworks Announces Participation in Upcoming Investor Conferences

26 Mar 2025 03:00:00 By Nasdaq GlobeNewswire

Zymeworks to Present Preclinical Data on T cell Engager and Antibody-Drug Conjugate Platforms in Six Posters at AACR Annual Meeting

25 Mar 2025 13:30:35 By Nasdaq GlobeNewswire

Zymeworks Provides Corporate Update and Reports Fourth Quarter and Full Year 2024 Financial Results

05 Mar 2025 13:05:00 By Nasdaq GlobeNewswire

Zymeworks Announces Achievement of $14 Million Milestone from GSK Collaboration

26 Feb 2025 03:00:00 By Nasdaq GlobeNewswire

Zymeworks Announces Participation in Upcoming Investor Conferences

25 Feb 2025 03:00:00 By Nasdaq GlobeNewswire

Zymeworks Announces Appointment of Oleg Nodelman to Board of Directors

18 Feb 2025 03:00:00 By Nasdaq GlobeNewswire

Zymeworks To Report Fourth Quarter and Full Year 2024 Financial Results and Host Conference Call on March 5, 2025

13 Feb 2025 03:00:00 By Nasdaq GlobeNewswire